Document is current
Any future updates will be listed below
-
Authors
Kronbichler, Andreas
- License Information
-
More Information
Article History
Received: 11 February 2026
Accepted: 7 March 2026
First Online: 5 April 2026
Declarations
:
: Andreas Kronbichler serves as the EiC of Rare Kidney Diseases and has received research grants from CSL (Vifor) and Otsuka and consultancy fees from Amgen, Argenx, AstraZeneca, Boehringer Ingelheim, CSL (Vifor), Delta4, GlaxoSmithKline, Novartis, Novo Nordisk, Otsuka, Roche, Sobi, Visterra and Walden Biosciences.
: Not applicable.
: Not applicable.
: Not applicable.
